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           Autoimmune diabetes is a chronic disease that occurs when the pancreas does not 
produce the insulin required to properly control blood glucose levels.  Also know as type 
1 diabetes, this disease is caused by an autoimmune attack of a person’s T-cells on islet β 
cells.  
           Exenatide, an incretin mimetic, is an analog to Glucagon-like peptide-1 (GLP-1).  
GLP-1 has many actions that improve glucose homeostasis such as potentiation of 
glucose-stimulated insulin secretions, promotion of β cell proliferation and survival, and 
inhibition of glucagon secretion.  Some studies have shown that exenatide and related 
compounds can protect β cells from apoptosis as well as block the migration of CD4+ T-
cells to islets.  Therefore, we hypothesize that exenatide may prevent the autoimmune 
development of diabetes in the non-obese diabetic (NOD) mouse model. 
           Thirty NOD mice were split into two groups.  Beginning at 6 weeks of age, Group 
1 (n=15) was given a 100ng dose subcutaneous of exenatide once daily and Group 2 
(n=15) was given a dose of saline once daily.  Glucose levels were monitored twice per 
week and animals were considered diabetic when blood glucose levels exceeded 300mg/dl.  
Once animals were considered diabetic, the pancreas was removed for histological analysis 
by staining for CD4+ T-cells and insulin. 
           By 30 weeks of age, 76.9% in Group 1 (exenatide) remained free of diabetes 
compared to 13.3% of animals in Group 2.  Immunohistochemical staining revealed higher 
concentrations of insulin producing cells and lower concentrations of CD3+ T-cell 
presence in treatment mice from Group 1. 
  
           Based on the results from this study, it appears that exenatide reduces the 
incidence of diabetes in NOD mice.  Animals treated with exenatide showed reduced 
blood glucose levels compared to those receiving saline, while immunohistochemical 
staining revealed insight into the possible mechanisms by which exenatide may function.  
From this study, it can be concluded that exenatide is an effective preventative treatment 
for the autoimmune development of diabetes. 
           To further study the mechanisms by which exenatide works, a second study was 
proposed.  In this study, we hypothesize that one mechanism by which exenatide delays or 
prevents the onset of type 1 diabetes is by modulating the migration of T-cells to the 
pancreas, thus preventing islet beta cell destruction and subsequent development of the 
disease. 
           Seventeen NOD mice were split into two groups.  Group 1a (n=9) received a 
100ng dose subcutaneous daily of exenatide while Group 2a (n=8) mice received a 100ul 
subcutaneous dose of saline daily. Glucose levels were monitored once per week and 
animals were considered diabetic when blood glucose levels exceeded 300mg/dl.   
           Mice expressing the luciferase gene have proven useful in research due to the 
ability to image their cells/tissue using an in vivo imaging system (IVIS) that detects the 
luminescence produced after administration with the enzyme substrate luciferin.  Isolated 
splenocytes from NOD L2G85 luciferase positive mice were transferred to the study 
group mice at individual euthanization time points. Bioluminescence imaging was used 3 
days following T cell transfer in order to visualize the location and/or pathway of the T 
cells. 
           Average photons in each experimental group were measured within a region of 
  
interest (ROI) at the approximate location of the pancreas using IVIS equipment.  The 
exenatide group was found to have an average of 1.190 x 105 photons whereas the saline 
group was found to have an average of 1.445 x 105 photons.  Bioluminescence imaging 
did show some reduction in the presence of transferred T-cells at the pancreas of 
exenatide-treated compared to saline mice.  Although the difference in measured photons 
is not significant between the two groups, we do not discredit our hypothesis.  We believe 



















           Autoimmune diabetes, otherwise known as type 1 diabetes or juvenile diabetes, is 
a chronic disease that occurs when the pancreas does not produce the insulin required to 
properly control blood glucose levels.  Autoimmune diabetes is commonly diagnosed in 
children, adolescents, and young adults after symptoms such as extreme fatigue, thirst, 
increased urination, and weight loss, arise.  The exact cause of autoimmune diabetes is 
unknown, but is thought to be a result of an environmental trigger that causes an 
overactive immune response in combination with genetic susceptibility.  Production of 
various autoantibodies, including islet cell antibody, islet cell protein tyrosine phosphatase, 
and glutamic acid decarboxylase, may contribute to an individual’s risk for the disease. 
The overactive immune response attacks islet β cells, destroying them and rendering the 
individual incapable of  producing insulin.  Islets are clusters of cells that make up 
approximately 1-2% of the pancreas.  About 70-80% of the cells within these clusters are 
beta (β) cells which produce insulin. 
           Insulin is released in response to increased levels of glucose in the blood due to 
ingestion of food.  Insulin initiates a signal transduction, which increases glucose uptake 
and storage, therefore decreasing blood glucose levels.  Individuals lacking those insulin 
producing β cells, type 1 diabetics, are unable to control their blood glucose levels 
internally and consequently require daily insulin therapy to survive.  Type 1 diabetics also 
need to monitor their diet and exercise while monitoring blood glucose levels often.   
           Lack of diabetes control may lead to various complications that are both 
burdensome and life-threatening.  Diabetics with poor control are at a higher risk for 
  
cataracts, hypertension, high cholesterol, damaged blood vessels, nerve damage, kidney 
disease, heart disease, stroke, blindness, and even death.  Although treatment for type 1 
diabetes is currently available, a preventative treatment that would significantly lower the 
incidence of diabetes, and these previously mentioned risks resulting from diabetes, has yet 
to be discovered. 
           Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the 
Gila monster (Heloderma suspectum) that was first isolated by Dr. John Eng in 1992.  
Exenatide is an analog to Glucagon-like peptide-1 (GLP-1).  GLP-1 improves glucose 
homeostasis by inducing glucose-dependent stimulation of insulin secretion while 
suppressing glucagon secretion (1,2).   
           Some studies have shown that exenatide and related compounds can protect β 
cells from apoptosis.  In vitro analysis of INS-1 cells has shown complete abrogation of 
apoptosis following pre-treatment with exenatide.  The same study also showed a decrease 
in the oxidative stress-inducing thioredoxin interacting protein (TXNIP) and the apoptotic 
factors caspase-3 and Bax after in vivo treatment with exenatide (2). 
           In vitro studies have also shown that exenatide reduces expression of JAK-1 and 
STAT-1, which mediate transcriptional effects of interferon-γ (IFN-γ) involved in beta cell 
apoptosis in the autoimmune development of type I diabetes.  Microarray analysis and 
quantitative real-time PCR showed decreases in JAK-1 and STAT-1 expression in both 
INS-1 cells and isolated human islets after co-culture with exenatide (3). 
           Furthermore, studies have shown that exenatide and related compounds can 
stimulate the proliferation and differentiation of insulin-secreting β-cells (4,5).  In addition, 
a compound related to exenatide, a dipeptidyl peptidase IV (DPPIV) inhibitor MK0431, 
  
has been previously shown to modulate T-cell migration to islet cells (6). 
           Exenatide is currently an injectable prescription medicine manufactured by Amylin 
Pharmaceuticals and Eli Lilly and Company.  It was approved by the FDA in April of 2005 





















           Exenatide, supplied by Amylin Pharmaceuticals and Eli Lilly and Company, was 
diluted in saline to obtain appropriate dosage of an injectable medication.  Multiple 
dilutions were performed to result in a final concentration of 100ng exenatide/0.1mL 
saline.  Exenatide solutions were then stored at -20oC.   
           The effects of exenatide were tested using the non-obese diabetic (NOD) mouse 
model.  The NOD mouse is genetically predisposed to developing diabetes and is currently 
the only animal model for autoimmune diabetes.  Female NOD mice develop diabetes 
earlier and at a higher incidence (90-100% by 30 weeks of age) than male NOD mice (40-
60% by 30-40 weeks of age). Thirty female NOD mice were split into two groups: 
treatment (group 1) versus control (group 2).  Beginning at 6 weeks of age, group 1 
(n=15) was given a 100ng subcutaneous dose of exenatide once daily (0.1ml volume) 
while group 2 (n=15) was given a 0.1ml dose of saline daily.  Glucose levels were 
monitored twice per week by snipping the animals’ tails and obtaining approximately 10µl 
of blood to be read on a standard glucometer (Ascensia Elite, Bayer).  Animals were 
considered diabetic when two consecutive blood glucose levels exceeded 300mg/dl.  Once 
animals were considered diabetic, the animal’s pancreas was removed for 







           Diabetes progression was measured from the primary study in order to analyze the 
effects of exenatide on the autoimmune development of diabetes.  It was found that group 
1 (treatment) had 76.9% of animals free of diabetes by 30 weeks of age whereas group 2 
(control) had 13.3% of animals free of diabetes by 30 weeks of age (Figure 1). 
 
Figure 1.  Diabetes progression, showing percent of animals free of diabetes.  Animals were considered 
diabetic when blood glucose levels exceeded 300 mg/dl for two consecutive measurements.  Group 1 
(treated with exenatide) had 76.9% of animals free of diabetes at 30 weeks of age, with disease diagnosis 
at 3 time points between 11 and 19 weeks.  Group 2 (treated with saline) had 13.3% of animals free of 
diabetes at 30 weeks of age, with disease diagnosis at various time points between 12 and 30 weeks.  
 
           Immunohistochemical staining on the pancreas was performed once animals were 
considered diabetic in order to gain insight into the mechanisms of exenatide.  Although 
the data could not be quantified, it was observed that untreated animals (Figures 2a and 
2b) had higher incidence of CD3+ stained islet cells than treated animals (Figure 2c). 
  
          
Figure 2.  CD3 stained islet beta cells from the pancreata of diabetic mice. Figure 2a shows an islet beta 
cell from mouse 5.1 (saline control animal) and Figure 2b shows a beta islet cell from mouse 4.4 (saline 
control animal).  Both cells are CD3+ illustrating attack of islet beta cells by CD3 T-cells.  Each mouse 
developed autoimmune diabetes due to the destruction of insulin producing islet beta cells.  
 
 
Figure 2.  Figure 2c shows an islet beta cell from mouse 1.4 (exenatide-treated animal).  This islet beta 
cell is CD3- illustrating no attack of by CD3 T-cells.  This mouse did not develop diabetes presumably due 









           Upon successful completion of the primary study in addition to the validation of 
our hypothesis, another study was proposed.  The mechanism of action of exenatide was 
tested also using the non-obese diabetic (NOD) mouse model.  Seventeen female NOD 
mice were split into two groups: treatment (group 1a) versus control (group 2a).  
Beginning at 6 weeks of age, group 1 (n=9) was given a 100ng subcutaneous dose of 
exenatide once daily while group 2 (n=8) was given a 0.1ml dose of saline daily.  Glucose 
levels were monitored once per week to track diabetes progression and animals were 
considered diabetic when two consecutive blood glucose levels exceeded 300mg/dl.   
           We chose a euthanization and imaging time point of 15 weeks, due to the fact that 
most NOD mice develop diabetes anywhere from 12 to 30 weeks of age.  At 15 weeks of 
age, splenocytes were isolated from luciferase-positive NOD L2G85 mice.  Isolated 
spleens were mechanically digested to a single cell suspension.  Viable splenocytes were 
counted using trypan blue, and  approximately 25 million isolated T-cells were transferred 
to the experimental groups by tail vein injection.  Three days post transfer, each mouse 
was individually anesthetized with isoflurance, given a 150µl dose of RediJect D-Luciferin 
(Caliper Life Sciences) intraperitoneal., and imaged ex vivo using the IVIS equipment.  
The abdomen of each mouse was opened for imaging and the pancreas located so that we 
could visualize the specific location of the transferred cells.  Once images were obtained, 
the mice were euthanized.   
           Images were analyzed by creating a region of interest (ROI) at the approximate 
location of the pancreas in each mouse image.  The photons were then measured from this 
ROI using a standardized scale for luminescence and recorded.  An average was obtained 
  
for both treatment and control groups for the photons measured within the ROI as well as 

























           In the secondary study, the presence of T-cells at the pancreas of treated versus 
untreated animals was quantified by using bioluminescent imaging.  An average number of 
photons from transferred luciferase-positive splenocytes at the pancreas was measured in 
each group as well as average blood glucose levels obtained immediately prior to imaging 
for comparison.  The exenatide group was found to have an average of 1.190 x 105 
photons whereas the saline group was found to have an average of 1.445 x 105 photons 
(Figure 3).  The p value for this data was found to be p=0.05.  Average blood glucose 
measurements obtained immediately prior to imaging show an average blood glucose level 
of 197mg/dl for the treated group and 287mg/dl for the untreated group (Figure 4).  The p 
value for this data was found to be p=0.2.  Of important note, the p values that were 
obtained for the data represented in Figures 3 and 4 exclude one exenatide-treated animal 
that had a low blood glucose and high number of photons.  The inclusion of this animal in 
the analyses skewed the data, giving a p value of p=0.4 for the blood glucose 
measurement comparison and a p value of p=0.2 for the comparison of photons measured.  
Figures 5 and 6 show representative bioluminescent images obtained from a treated and 




Figure 3. Average photons measured within region of interest (ROI) of exenatide (treated) and saline 
(control) mice.  Images were taken by IVIS equipment 3 days following transfer of approximately 25 
million luciferase-positive splenocytes.  Data analysis yielded a p value of p=0.05 
            
 
Figure 4. Average blood glucose levels of exenatide (treated) and saline (control) mice.  Blood glucose 
levels were measured immediately prior to luminescence imaging via IVIS equipment. Data analysis 






Figure 5. IVIS image taken from exenatide cage # 1 mouse #1.  Photons measured in the ROI were 
observed to be 1.0311 x 105  
 
 
Figure 6. IVIS image taken from saline cage #3 mouse #3.  Photons measured in the ROI were observed 
to be 1.6563 x 105  
 
 
           For saline mice, regression analysis showed a positive linear relationship with an R-
squared of 41.7% (Figure 7).  One exenatide-treated mouse had a low blood glucose and 
high number of photons, and this skewed the data from this group.  With the inclusion of 
  
this animal in the regression analysis, the R-squared value was only 6.6%.  However, when 
this outlier was removed from analysis, there also appeared to be a positive linear 
relationship between blood glucose levels and number of photons in the exenatide group 
as well with an R-squared of 48.8% (Figure 8).  These correlations are relatively weak, 
but there still seems to be a relationship between the data. 
 
 
Figure 7. Regression analysis of saline-treated mice showed a positive linear relationship of photons 





Figure 8. Regression analysis of exenatide-treated mice, with removal of the outlier, showed a positive 
























           Our primary study shows that exenatide significantly reduces the incidence of 
diabetes in NOD mice (Figure 1).  Animals treated with exenatide showed reduced blood 
glucose levels and reduced levels of T-cells in immunohistochemical staining of the 
pancreas compared to those receiving saline (Figure 2).  This led our laboratory group to 
perform a secondary study to evaluate the possible mechanism of action of exenatide in 
reducing the incidence of diabetes.  A study published in 2009 by another laboratory 
showed that the DPPIV inhibitor MK0431 was able to modulate the migration of T-cells 
to islets in transplanted NOD mice (6).  DPPIV inhibitors are a class of compounds that 
are related to the GLP-1 agonists (including exenatide).  DPPIV is a natural enzyme in the 
body that degrades GLP-1.  Thus, DPPIV inhibitors result in increased levels of GLP-1.  
Treatment with exenatide and other GLP-1 agonists results in high levels of exogenous 
GLP-1.  We hypothesized that, like the related DPPIV inhibitor, exenatide may also 
modulate T-cell migration to the pancreas and therefore be able to reduce destruction of 
islets by T-cells.  To test this, we transferred luciferase-positive NOD T-cells into treated 
or control NOD mice and used bioluminescent imaging to track the migration of these 
cells.  
           Our secondary study shows that bioluminescent imaging did show some reduction 
in the presence of transferred T-cells at the pancreas of exenatide-treated animals 
compared to controls (Figure 3).  However, the difference was not significant.  To test the 
correlation between presence of T-cells at the pancreas and blood glucose levels, blood 
glucose measurements were taken immediately prior to imaging.  Higher average blood 
glucose levels in saline mice correlated with a higher average number of photons at the 
  
region of interest (ROI), while lower average blood glucose levels in exenatide-treated 
mice correlated with a lower average number of photons at the region of interest (ROI).   
           Although our secondary study did not produce significant results, we do not 
discredit our hypothesis.  Many difficulties arose throughout the duration of the 
experiment that may have negatively affected our data.  Given that diabetes diagnosis time 
points are varied, and therefore unknown for any specific mouse, visualization of T-cells in 
the ROI is extremely difficult to obtain.  By only imaging our mice at 15 weeks of age, we 
were extremely limited with our analysis of the hypothesis.  In addition, the experimental 
groups used for this study were small.  In order to address these concerns, experiments 
should be repeated with modifications for a better analysis of our hypothesis. 
           We suggest that our next steps should be to repeat the secondary experiments 
using larger experimental group sizes as well as incorporating additional time points of 
imaging and euthanization.  We also suggest obtaining in vivo images until the presence of 
T-cells is observed, in which we would then proceed to obtain ex vivo images.  By adding 
additional imaging and euthanization time points and/or primarily obtaining in vivo images 
before proceeding to ex vivo images, we would allow a larger window of time to obtain 
appropriate images at various points of diabetes progression.  We strongly believe that 
these modifications would yield significant results. 
           The effects of exenatide on the autoimmune development of diabetes has multiple 
positive consequences for many individuals in our world today.  While effective treatment 
for autoimmune diabetes is well-known, no preventative measures exist.  Exenatide may 
prove to be a prospect for this preventative treatment.  Though many issues have been 
revealed for the application of exenatide in a clinical setting, we strongly believe that this 
  
preventative treatment will substantially change how type I diabetes is approached in the 
future.  
           Type I diabetes is generally diagnosed once the patient is already in critical 
condition, when approximately 90% of the islet beta cells are already destroyed.  The first 
weeks of a diabetes diagnosis, typically known as the “honeymoon phase”, is a primary 
target for successful application of exenatide.  When islet beta cells are still present, we 
believe that rapid treatment with exenatide may protect the remaining islets and 
subsequently prevent the development of autoimmune diabetes.  If this application were 
going to be used, further studies should be done to determine appropriate time points for 
effective treatment.  A potential study could include the use of NOD mice, in which blood 
glucose levels would need to be measured twice per week, and treatment with exenatide 
or control treatment with saline would need to be initiated at the time of initial diabetes 
diagnosis.  Results from a study such as this would produce a better understanding of this 
potential application of exenatide. 
           In addition,  we believe that the possibility for genetic testing for specific markers 
or autoantibodies may assist with identifying those at risk for development of the disease.  
This in addition to a family history of diabetes, or any autoimmune condition, may present 
substantial reason to believe that the particular individual is largely at risk for developing 
the disease.  Again, this may prove to be a target for the clinical application of exenatide. 
           As previously mentioned, treatment for type 1 diabetes is currently available, but a 
preventative treatment that would significantly lower the incidence of diabetes, and the 
risks associated with diabetes, has yet to be discovered.  Our studies outlined in this thesis 
show that exenatide significantly reduces the incidence of diabetes in NOD mice by a 
  
mechanism that reduces the presence of transferred T-cells at the pancreas of exenatide-
treated animals compared to controls.  This shows that exenatide is involved in protection 
of islet beta cells from an autoimmune attack of T-cells, subsequently preventing the 
development of type I diabetes.  Therefore, we believe that exenatide may prove to be 





















1. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on 
glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy 
men. Horm Res 1998; 49(5):221-225. 
2. Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits β-cell apoptosis by 
decreasing thioredoxin-interacting protein. Biochem Biophys Res Comm 2006; 346:1067-
1074. 
3. Couto FM, Minn AH, Pise-Masison CA, Radonovich M, Brady JN, Hanson M, et al. 
Exenatide blocks JAK-1 STAT-1 in pancreatic beta cells. Metabolism Clinical and 
Experimental 2007; 56:915-918. 
4. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell 
replication and neogenesis in increased β-cell mass and improved glucose tolerance in 
diabetic rats. Diabetes 1999; 48:2270-2276. 
5. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and 
exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in 
persistently improved glucose homeostasis at adult age. Diabetes 2001; 50:1562-1570. 
6. Kim S-J, Nian C, Doudet DJ, McIntosh CHS. Dipeptidyl peptidase IV inhibition with 
MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell 
modulation. Diabetes 2009; 58:641-651. 
7. PubMed Health.  Type I diabetes: Insulin-dependent diabetes; Juvenile onset diabetes; 
Diabetes - type 1.  May, 2010. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001350/ 




             
            
              
 
 
 
 
 
 
 
 
